FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086486486> ?p ?o ?g. }

• W2086486486 endingPage "1264" @default.
• W2086486486 startingPage "1254" @default.
• W2086486486 abstract "The role of radiotherapy (RT) seems established for patients with low-grade gliomas with poor prognostic factors. Three-dimensional (3D) magnetic resonance spectroscopy imaging (MRSI) has been reported to be of value in defining the extent of glioma infiltration. We performed a study examining the impact MRSI would have on the routine addition of 2–3-cm margins around MRI T2-weighted hyperintensity to generate the treatment planning clinical target volume (CTV) for low-grade gliomas. Twenty patients with supratentorial gliomas WHO Grade II (7 astrocytomas, 6 oligoastrocytomas, 7 oligodendrogliomas) underwent MRI and MRSI before surgery. The MRI was contoured manually; the regions of interest included T2 hyperintensity and, if present, regions of contrast enhancement on T1-weighted images. The 3D-MRSI peak parameters for choline and N-acetyl-aspartate, acquired voxel-by-voxel, were categorized using a choline/N-acetyl-aspartate index (CNI), a tool for quantitative assessment of tissue metabolite levels, with CNI 2 being the lowest value corresponding to tumor. CNI data were aligned to MRI and displayed as 3D contours. The relationship between the anatomic and metabolic information on tumor extent was assessed by comparing the CNI contours and other MRSI-derived metabolites to the MRI T2 volume. The limitations in the size of the region “excited” meant that MRSI could be used to evaluate only a median 68% of the T2 volume (range 38–100%), leaving the volume T2c. The CNI 2 volume (median 29 cm3, range 10–73) was contained totally within the T2c in 55% of patients. In the remaining patients, the volume of CNI 2 extending beyond the T2c was quite small (median 2.3 cm3, range 1.4–5.2), but was not distributed uniformly about the T2c, extending up to 22 mm beyond it. Two patients demonstrated small regions of contrast enhancement corresponding to the regions of highest CNI. Other metabolites, such as creatine and lactate, seem useful for determining less and more radioresistant areas, respectively. Metabolically active tumor, as detected by MRSI, is restricted mainly to the T2 hyperintensity in low-grade gliomas, but can extend outside it in a limited and nonuniform fashion up to 2 cm. Therefore, a CTV including T2 and areas of CNI extension beyond the T2 hyperintensity would result in a reduction in the size and a change in the shape of the standard clinical target volumes generated by adding uniform margins of 2–3 cm to the T2 hyperintensity." @default.
• W2086486486 created "2016-06-24" @default.
• W2086486486 creator A5031916033 @default.
• W2086486486 creator A5039465135 @default.
• W2086486486 creator A5041182571 @default.
• W2086486486 creator A5042076336 @default.
• W2086486486 creator A5046287975 @default.
• W2086486486 creator A5046465813 @default.
• W2086486486 creator A5076663538 @default.
• W2086486486 creator A5079486612 @default.
• W2086486486 creator A5090516617 @default.
• W2086486486 creator A5090590010 @default.
• W2086486486 date "2002-08-01" @default.
• W2086486486 modified "2023-10-02" @default.
• W2086486486 title "Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy" @default.
• W2086486486 cites W1266779413 @default.
• W2086486486 cites W1964123950 @default.
• W2086486486 cites W1965662896 @default.
• W2086486486 cites W1968023782 @default.
• W2086486486 cites W1982182795 @default.
• W2086486486 cites W1982595288 @default.
• W2086486486 cites W1990556342 @default.
• W2086486486 cites W1995577320 @default.
• W2086486486 cites W1995727099 @default.
• W2086486486 cites W2001569479 @default.
• W2086486486 cites W2002291505 @default.
• W2086486486 cites W2005331182 @default.
• W2086486486 cites W2013558819 @default.
• W2086486486 cites W2032443466 @default.
• W2086486486 cites W2036369046 @default.
• W2086486486 cites W2055570731 @default.
• W2086486486 cites W2070581888 @default.
• W2086486486 cites W2071354916 @default.
• W2086486486 cites W2075184473 @default.
• W2086486486 cites W2076566420 @default.
• W2086486486 cites W2090298833 @default.
• W2086486486 cites W2093110246 @default.
• W2086486486 cites W2100791391 @default.
• W2086486486 cites W2107748921 @default.
• W2086486486 cites W2127988996 @default.
• W2086486486 cites W2135526482 @default.
• W2086486486 cites W2140866432 @default.
• W2086486486 cites W2143908930 @default.
• W2086486486 cites W2146933354 @default.
• W2086486486 cites W2150340231 @default.
• W2086486486 cites W2157568116 @default.
• W2086486486 cites W2161067577 @default.
• W2086486486 cites W2168156981 @default.
• W2086486486 cites W2169537399 @default.
• W2086486486 cites W2315052252 @default.
• W2086486486 cites W2334686589 @default.
• W2086486486 cites W4231743520 @default.
• W2086486486 doi "https://doi.org/10.1016/s0360-3016(02)02869-9" @default.
• W2086486486 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12128127" @default.
• W2086486486 hasPublicationYear "2002" @default.
• W2086486486 type Work @default.
• W2086486486 sameAs 2086486486 @default.
• W2086486486 citedByCount "109" @default.
• W2086486486 countsByYear W20864864862012 @default.
• W2086486486 countsByYear W20864864862013 @default.
• W2086486486 countsByYear W20864864862014 @default.
• W2086486486 countsByYear W20864864862015 @default.
• W2086486486 countsByYear W20864864862016 @default.
• W2086486486 countsByYear W20864864862017 @default.
• W2086486486 countsByYear W20864864862018 @default.
• W2086486486 countsByYear W20864864862019 @default.
• W2086486486 countsByYear W20864864862020 @default.
• W2086486486 countsByYear W20864864862021 @default.
• W2086486486 countsByYear W20864864862022 @default.
• W2086486486 countsByYear W20864864862023 @default.
• W2086486486 crossrefType "journal-article" @default.
• W2086486486 hasAuthorship W2086486486A5031916033 @default.
• W2086486486 hasAuthorship W2086486486A5039465135 @default.
• W2086486486 hasAuthorship W2086486486A5041182571 @default.
• W2086486486 hasAuthorship W2086486486A5042076336 @default.
• W2086486486 hasAuthorship W2086486486A5046287975 @default.
• W2086486486 hasAuthorship W2086486486A5046465813 @default.
• W2086486486 hasAuthorship W2086486486A5076663538 @default.
• W2086486486 hasAuthorship W2086486486A5079486612 @default.
• W2086486486 hasAuthorship W2086486486A5090516617 @default.
• W2086486486 hasAuthorship W2086486486A5090590010 @default.
• W2086486486 hasConcept C103191249 @default.
• W2086486486 hasConcept C126838900 @default.
• W2086486486 hasConcept C143409427 @default.
• W2086486486 hasConcept C146638467 @default.
• W2086486486 hasConcept C2778227246 @default.
• W2086486486 hasConcept C2989005 @default.
• W2086486486 hasConcept C502942594 @default.
• W2086486486 hasConcept C54170458 @default.
• W2086486486 hasConcept C71924100 @default.
• W2086486486 hasConcept C96781048 @default.
• W2086486486 hasConceptScore W2086486486C103191249 @default.
• W2086486486 hasConceptScore W2086486486C126838900 @default.
• W2086486486 hasConceptScore W2086486486C143409427 @default.
• W2086486486 hasConceptScore W2086486486C146638467 @default.
• W2086486486 hasConceptScore W2086486486C2778227246 @default.
• W2086486486 hasConceptScore W2086486486C2989005 @default.
• W2086486486 hasConceptScore W2086486486C502942594 @default.

• next